Literature DB >> 21507971

Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells.

Nicole Sunseri1, Meagan O'Brien, Nina Bhardwaj, Nathaniel R Landau.   

Abstract

The lentiviral accessory protein Vpx is thought to facilitate the infection of macrophages and dendritic cells by counteracting an unidentified host restriction factor. Although human immunodeficiency virus type 1 (HIV-1) does not encode Vpx, the accessory protein can be provided to monocyte-derived macrophages (MDM) and monocyte-derived dendritic cells (MDDC) in virus-like particles, dramatically enhancing their susceptibility to HIV-1. Vpx and the related accessory protein Vpr are packaged into virions through a virus-specific interaction with the p6 carboxy-terminal domain of Gag. We localized the minimal Vpx packaging motif of simian immunodeficiency virus SIVmac(239) p6 to a 10-amino-acid motif and introduced this sequence into an infectious HIV-1 provirus. The chimeric virus packaged Vpx that was provided in trans and was substantially more infectious on MDDC and MDM than the wild-type virus. We further modified the virus by introducing the Vpx coding sequence in place of nef. The resulting virus produced Vpx and replicated efficiently in MDDC and MDM. The virus also induced a potent type I interferon response in MDDC. In a coculture system, the Vpx-containing HIV-1 was more efficiently transmitted from MDDC to T cells. These findings suggest that in vivo, Vpx may facilitate transmission of the virus from dendritic cells to T cells. In addition, the chimeric virus could be used to design dendritic cell vaccines that induce an enhanced innate immune response. This approach could also be useful in the design of lentiviral vectors that transduce these relatively resistant cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21507971      PMCID: PMC3126535          DOI: 10.1128/JVI.00346-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate.

Authors:  J W Balliet; D L Kolson; G Eiger; F M Kim; K A McGann; A Srinivasan; R Collman
Journal:  Virology       Date:  1994-05-01       Impact factor: 3.616

2.  Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA.

Authors:  A H Kaplan; P Krogstad; D J Kempf; D W Norbeck; R Swanstrom
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

3.  Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.

Authors:  W Paxton; R I Connor; N R Landau
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

4.  Localization of the Vpx packaging signal within the C terminus of the human immunodeficiency virus type 2 Gag precursor protein.

Authors:  X Wu; J A Conway; J Kim; J C Kappes
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

5.  A dominant block to HIV-1 replication at reverse transcription in simian cells.

Authors:  Carsten Münk; Stephanie M Brandt; Ginger Lucero; Nathaniel R Landau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-04       Impact factor: 11.205

6.  The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.

Authors:  N K Heinzinger; M I Bukrinsky; S A Haggerty; A M Ragland; V Kewalramani; M A Lee; H E Gendelman; L Ratner; M Stevenson; M Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

7.  Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions.

Authors:  Y L Lu; P Spearman; L Ratner
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products.

Authors:  E D Garrett; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.

Authors:  R I Connor; B K Chen; S Choe; N R Landau
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

10.  Progression to AIDS in the absence of a gene for vpr or vpx.

Authors:  J S Gibbs; A A Lackner; S M Lang; M A Simon; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more
  76 in total

1.  The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.

Authors:  Xiaoxia Wang; Zhujun Ao; Liyu Chen; Gary Kobinger; Jinyu Peng; Xiaojian Yao
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages.

Authors:  Baek Kim; Laura A Nguyen; Waaqo Daddacha; Joseph A Hollenbaugh
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

3.  Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection.

Authors:  Thomas D Norton; Takuya Tada; Rebecca Leibowitz; Verena van der Heide; Dirk Homann; Nathaniel R Landau
Journal:  Mol Ther       Date:  2020-05-20       Impact factor: 11.454

4.  SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells.

Authors:  Hanna-Mari Baldauf; Xiaoyu Pan; Elina Erikson; Sarah Schmidt; Waaqo Daddacha; Manja Burggraf; Kristina Schenkova; Ina Ambiel; Guido Wabnitz; Thomas Gramberg; Sylvia Panitz; Egbert Flory; Nathaniel R Landau; Serkan Sertel; Frank Rutsch; Felix Lasitschka; Baek Kim; Renate König; Oliver T Fackler; Oliver T Keppler
Journal:  Nat Med       Date:  2012-11       Impact factor: 53.440

5.  A Highly Active Isoform of Lentivirus Restriction Factor SAMHD1 in Mouse.

Authors:  Nicolin Bloch; Sabine Gläsker; Poojitha Sitaram; Henning Hofmann; Caitlin N Shepard; Megan L Schultz; Baek Kim; Nathaniel R Landau
Journal:  J Biol Chem       Date:  2016-12-05       Impact factor: 5.157

6.  Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses.

Authors:  Julia Bitzegeio; Marissa Sampias; Paul D Bieniasz; Theodora Hatziioannou
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

7.  Degradation of SAMHD1 by Vpx Is Independent of Uncoating.

Authors:  Paula Jáuregui; Eric C Logue; Megan L Schultz; Stephanie Fung; Nathaniel R Landau
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

8.  Dendritic cell-lymphocyte cross talk downregulates host restriction factor SAMHD1 and stimulates HIV-1 replication in dendritic cells.

Authors:  Bin Su; Marina Elizabeth Biedma; Alexandre Lederle; Maryse Peressin; Mélanie Lambotin; Alizé Proust; Thomas Decoville; Sylvie Schmidt; Géraldine Laumond; Christiane Moog
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

9.  Tailored HIV-1 vectors for genetic modification of primary human dendritic cells and monocytes.

Authors:  Stéphanie Durand; Xuan-Nhi Nguyen; Jocelyn Turpin; Stephanie Cordeil; Nicolas Nazaret; Séverine Croze; Renaud Mahieux; Joël Lachuer; Catherine Legras-Lachuer; Andrea Cimarelli
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1.

Authors:  Tommy E White; Alberto Brandariz-Nuñez; Jose Carlos Valle-Casuso; Sarah Amie; Laura Nguyen; Baek Kim; Jurgen Brojatsch; Felipe Diaz-Griffero
Journal:  Virology       Date:  2012-11-13       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.